MannKind Corp

• 3 Drug Catalysts to Watch in 2013

  By Brandy Betz - May 9, 2013 | Tickers: MNKD, MRK, PFE, RIGL, SNY

  Pharmaceutical investors: start your engines! We’re into the second quarter of 2013 and some major catalysts lurk right around the corner.

  Merck (NYSE: MRK) has a Food and Drug Administration meeting for a potential first-in-class insomnia treatment. The drug offers a better safety profile than the currently available treatments. MannKind (NASDAQ: MNKD)  returns with additional trial data that has delayed its anticipated diabetes inhalant. And Rigel Pharmaceuticals (NASDAQ: RIGLmore »)

• Did This Stock Deserve This Sudden Upward Swing?

  By Jeremiah Feliciano - May 8, 2013 | Tickers: MNKD, NVS, VRTX

  Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged from $52.87 on April 18 to a 12-year high of $85.90 per share on April 19 after the company reported positive outcomes from the Phase II clinical trial of its experimental drug, VX-661. Last time the stock witnessed such as rapid growth was on November 3, 2000, when the prices reached $93.87 a share.

  It’s only Phase II

  The drug more »

• Three Outside the Box Biotechs

  By Streetwise Reports - April 1, 2013 | Tickers: BDX, LGND, MNKD, ONXX, UNIS

  By George S. Mack of The Life Sciences Report

  I had a really nice chat with Griffin Securities analyst and scientific director Keith Markey about a wide-ranging group of topics. My goal is to always talk about individual biotech and sometimes medtech stocks, but we got started on another subject right away. Although he’s been an analyst for 25 years now, Markey started his career as a molecular biologist more »

• 3 Bio-Techs Insiders Love

  By Mohsin Saeed - March 19, 2013 | Tickers: INFI, MNKD, SQNM

  The biotechnology industry has given exceptional returns in the last couple of years. Quite a few stocks have soared due to FDA approval of their respective drugs. The high number of expiring patents has also forced larger bio-pharmaceutical companies to adopt aggressive acquisition strategies.

  The following three companies have seen strong insider buying during the last six months. This can be an indication of positive catalysts approaching because insiders have more »

• 3 Bio-Pharmaceuticals Insiders Love

  By Mohsin Saeed - February 28, 2013 | Tickers: MNKD, MACK, TSRO

  Insiders are privy to information that is not available to other investors interested in a stock. Considering the fact that our stock picks and the overall stock market is driven by information, this information edge can make all the difference. This is the very reason there is an entire investment strategy on following insider trades. Following these trades gives investors an edge over others who are totally dependent on publicly more »

• 100% Upside on these Bio-techs

  By Mohsin Saeed - January 31, 2013 | Tickers: GALE, MNKD, TEVA

  The approval of a drug candidate is one of the most important events for any biopharmaceutical company, and the approval event becomes even more important for biopharmaceuticals with a limited pipeline. This is because the valuations of the company are strongly affected by the approval or rejection of its candidate. The following two companies have major candidates nearing the end of Phase III clinical trials, and these drugs can significantly more »

• A Biopharmaceutical Lottery Ticket

  By Mohsin Saeed - January 25, 2013 | Tickers: LLY, MNKD, PFE

  The recent failure of Pfizer (NYSE: PFE) in selling its inhalable insulin Exubera is forcing investors to seriously discount the commercial potential of inhalable insulin. It was the primary reason that major players such as Eli Lilly (NYSE: LLY) abandoned their own inhalable insulin products.

  The bad market sentiment about inhalable insulin has seriously affected the valuations of MannKind (NASDAQ: MNKD). This is the only reason it is trading at more »

• Biopharma Stocks: Companies That Develops Studies For Type 2 Diabetes

  By Jorge Aura - December 11, 2012 | Tickers: AZN, BMS, JNJ, MNKD

  According to the World Health Organization (WHO), it is estimated that 346 million people around the world suffer from diabetes. Only in U.S. 26 million people suffer this illness.  Analysts reported that this market could jump from $35 billion to $50 billion by 2016. This situation provides an attractive market for large pharmaceutical and small biotech companies that want to look for a gap in the sector.

  Currently, the more »

• Buy or Hold This Biopharmaceutical

  By Krishna Maheshwari - August 15, 2012 | Tickers: LLY, MNKD, NKTR, NVO, PFE

  Mannkind (NASDAQ: MNKD) is an inhalable drug company developing a fast acting, inhalable insulin (branded Afrezza) that is superior to any other insulin in the market today and a likely blockbuster drug.  They have completed phase III clinical trials and received no drug efficacy related pushback from the FDA, but have received two CRLs recently.  They are currently conducting two clinical trials to prove that the inhaler they intend to more »

• The Good, the Bad, and the Ugly

  By Alexander Pavone - July 2, 2012 | Tickers: AAPL, CSCO, MNKD, SIRI

  Over on my old trading desk at RBC Capital Markets, we used to play a little stock picking game based off the Sergio Leone title starring Clint Eastwood. The goal of course was to choose 3 stocks, one good, one bad and one ugly and evaluate the action in each over the coming months. The idea was simply that the good should keep getting better, the bad should continue to more »

• Bull Case for Mannkind

  By Krishna Maheshwari - May 24, 2012 | Tickers: ALKS, LLY, MNKD, NVO, PFE

  Mannkind (NASDAQ: MNKD) is a multi-bagger from its current levels in the next 1-3 years.

  This article will dive into the key elements of the investment thesis behind why I think Mannkind has such an enomous potential and will also highlight some of the risks.  As a summary, we have a serial entrepreneur with multiple successes in the CEO.  The drug has gone through Phase III clinical trials with no more »

• Can These Biotechs Make You Money In 2012?

  By Robert Fisher - January 14, 2012 | Tickers: ARIA, DNDN, HGSI, ILMN, MNKD

  The biotech group is among the largest in the market in terms of the number of companies. They trade with perhaps the highest volatility in the market and move heavily on optimism of future successful drugs. The five biotech stocks on my radar today are Dendreon Corp. (NASDAQ: DNDN), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Human Genome Sciences (NASDAQ: HGSI), Illumina Inc. (NASDAQ: ILMN) and MannKind Corp. (NASDAQ: MNKD). The outlook more »